ZIOPHARM prices underwritten public offering of 9,600,000 shares of common stock

ZIOPHARM Oncology, Inc. today announced the pricing of an underwritten public offering of 9,600,000 shares of its common stock at a price to the public of $5.75 per share. The public offering is expected to close on or about February 8, 2011, subject to customary closing conditions. In addition, ZIOPHARM Oncology has granted the underwriter a 30-day option to purchase up to 1,440,000 additional shares of common stock to cover overallotments.

Barclays Capital Inc. is acting as sole book-running manager in this offering.

The securities described above are being offered by ZIOPHARM pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on May 13, 2010. Copies of the prospectus supplement and related prospectus, when available, may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; [email protected] (phone: 888-603-5847).